Assessing iPSC reprogramming methods for their suitability in translational medicine
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
The discovery of the ability to induce somatic cells to a pluripotent state through the overexpression of specific transcription factors has the potential to transform the ways in which pharmaceutical agents and cellular transplantation therapies are developed. Proper utilization of the technology to generate induced pluripotent stem cells (iPSCs) requires that researchers select the appropriate reprogramming method for generating iPSCs so that the resulting iPSCs can be transitioned towards clinical applications effectively. This article reviews all of the currently available reprogramming techniques with a focus on critiquing them on the basis of their utility in translational medicine. J. Cell. Biochem. 113: 3061‐3068, 2012. Published 2012. This article is a U.S. Government work and is in the public domain in the USA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y.-H., Li, H., Lau, F., Ebina, W., Mandal, P. K., Smith, Z. D., Meissner, A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.08.012 · Cited by 2,662
Human induced pluripotent stem cells free of vector and transgene sequences
Yu, J., Hu, K., Smuga-Otto, K., Tian, S., Stewart, R., Slukvin, I. I., & Thomson, J. A. (2009) · Science · doi:10.1126/science.1172482 · Cited by 2,386
Generation of Human Induced Pluripotent Stem Cells by Direct Delivery of Reprogramming Proteins
Kim, D., Kim, C.-H., Moon, J.-I., Chung, Y.-G., Chang, M.-Y., Han, B.-S., Ko, S., Yang, E., Cha, K. Y., Lanza, R., et al. (2009) · Cell stem cell · doi:10.1016/j.stem.2009.05.005 · Cited by 1,814
Chemically defined conditions for human iPSC derivation and culture
Chen, G., Gulbranson, D. R., Hou, Z., Bolin, J. M., Ruotti, V., Probasco, M. D., Smuga-Otto, K., Howden, S. E., Diol, N. R., Propson, N. E., et al. (2011) · Nature Methods · doi:10.1038/nmeth.1593 · Cited by 1,447
FUSAKI, N., BAN, H., NISHIYAMA, A., SAEKI, K., & HASEGAWA, M. (2009) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.85.348 · Cited by 1,411 · cited 1×
“The first published study using Sendai virus for human iPSC reprogramming reported that BJ1 neonatal fibroblasts and adult human dermal fibroblasts were reprogrammed at an efficiency of 1% within 25 days of infection [Fusaki et al., 2009].”
BackgroundMorin, R. D., O’Connor, M. D., Griffith, M., Kuchenbauer, F., Delaney, A., Prabhu, A.-L., Zhao, Y., McDonald, H., Zeng, T., Hirst, M., et al. (2008) · Genome Research · doi:10.1101/gr.7179508 · Cited by 1,110
A nonviral minicircle vector for deriving human iPS cells
Jia, F., Wilson, K. D., Sun, N., Gupta, D. M., Huang, M., Li, Z., Panetta, N. J., Chen, Z. Y., Robbins, R. C., Kay, M. A., et al. (2010) · Nature Methods · doi:10.1038/nmeth.1426 · Cited by 734 · cited 1×
“A minicircle vector was produced with Lin28, GFP, Nanog, Sox2, and Oct4 and used to reprogram human adipose stem cells [Jia et al., 2010; Narsinh et al., 2011].”
MethodInduced Pluripotent Stem Cell Generation Using a Single Lentiviral Stem Cell Cassette
Sommer, C. A., Stadtfeld, M., Murphy, G. J., Hochedlinger, K., Kotton, D. N., & Mostoslavsky, G. (2009) · Stem Cells · doi:10.1634/stemcells.2008-1075 · Cited by 676 · cited 1×
“The incorporation of loxP sites into this type of vector has made it the lentivector of choice for making iPSCs [Chang et al., 2009; Sommer et al., 2009].”
BackgroundSeki, T., Yuasa, S., Oda, M., Egashira, T., Yae, K., Kusumoto, D., Nakata, H., Tohyama, S., Hashimoto, H., Kodaira, M., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.06.003 · Cited by 584
Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells
Zhou, W., & Freed, C. R. (2009) · Stem Cells · doi:10.1002/stem.201 · Cited by 538
Cited by
Current status of pluripotent stem cells: moving the first therapies to the clinic
Kimbrel, E. A., & Lanza, R. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4738 · Cited by 261
Gledhill, K., Guo, Z., Umegaki-Arao, N., Higgins, C. A., Itoh, M., & Christiano, A. M. (2015) · PLOS ONE · doi:10.1371/journal.pone.0136713 · Cited by 132
“The different methods used for reprogramming of somatic cells into a pluripotent state is one of the most likely reasons for this variability [34] and is an issue which must be addressed fully before the generation of organs solely from multiple iPSC types can be readily replicated in different laboratories that do no…”
MethodKozlov, A. M., Lone, A., Betts, D. H., & Cumming, R. C. (2020) · Scientific Reports · doi:10.1038/s41598-020-65193-9 · Cited by 94
Azuma, K., & Yamanaka, S. (2016) · Regenerative Therapy · doi:10.1016/j.reth.2016.01.009 · Cited by 63
Design, Assembly, Production, and Transfection of Synthetic Modified mRNA
Oh, S., & Kessler, J. A. (2018) · Methods · doi:10.1016/j.ymeth.2017.10.008 · Cited by 58
“When compared against other methods, mRNAmediated reprogramming of somatic cells to pluripotent stem cells resulted in 10–100 times more efficient and faster emergence of colonies while still maintaining the lowest aneuploidy of the treated cells [10,48,49].”
ResultWang, L., Su, Y., Huang, C., Yin, Y., Chu, A., Knupp, A., & Tang, Y. (2019) · Biology Open · doi:10.1242/bio.047225 · Cited by 39
Strategies to Improve the Safety of iPSC-Derived β Cells for β Cell Replacement in Diabetes
Pellegrini, S., Zamarian, V., & Sordi, V. (2022) · Transplant International · doi:10.3389/ti.2022.10575 · Cited by 38
Dey, C., Raina, K., Haridhasapavalan, K. K., Thool, M., Sundaravadivelu, P. K., Adhikari, P., Gogoi, R., & Thummer, R. P. (2021) · Recent Advances in iPSC Technology · doi:10.1016/b978-0-12-822231-7.00011-4 · Cited by 23
Metadata
- Authors
- Rao, M. S., & Malik, N.
- Venue
- Journal of Cellular Biochemistry
- Publisher
- Wiley
- Published
- 2012-08-09
- Volume
- 113
- Issue
- 10
- Pages
- 3061-3068
- ISSN
- 0730-2312 (ISSN-L)
- 1097-4644
- OpenAlex
- W2075136524
- Cited by
- 127
- References
- 15
- FWCI
- 3.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.